Differential modulation of cytokine production by drugs: implications for therapy in heart failure

Journal of Molecular and Cellular Cardiology
A MatsumoriS Sasayama

Abstract

We studied the effects of various phosphodiesterase (PDE) III inhibitors: amrinone, pimobendan and vesnarinone: a PDE IV inhibitor (Ro 20-1724) and a PDE V inhibitor (E-4021) on the production of cytokines which have been shown to depress myocardial function. Recently developed inotropic agents which inhibit PDE III activity have produced short-term hemodynamic benefits in patients with advanced heart failure, but long-term treatment with these agents has an adverse effect on survival. However, vesnarinone, which has been shown to improve survival dramatically, has an immunomodulating effect and inhibits the production of cytokines. Peripheral blood mononuclear cells obtained from healthy human subjects were stimulated with lipopolysaccharide and each PDE inhibitor was added. After 24 h of incubation, tumor necrosis factor alpha (TNF-alpha), interleukin 1 beta (IL-1 beta) and IL-6 in the culture supernatants were measured by an enzyme-linked immunosorbent assay. All three PDE III inhibitors, amrinone, pimobendan and vesnarinone, inhibited TNF-alpha production, but vesnarinone's inhibitory effect was the most prominent. Amrinone and pimobendan enhanced IL-1 beta production, whereas vesnarinone had no effect. Vesnarinone inhibite...Continue Reading

Citations

Sep 21, 2000·Transplantation Proceedings·K P PlatzA R Mueller
May 30, 2002·Transplantation Proceedings·A R MuellerP Neuhaus
Sep 2, 1998·Transplantation Proceedings·A R MuellerP Neuhaus
Mar 6, 1998·International Journal of Cardiology·A Matsumori
Mar 15, 2000·International Journal of Cardiology·M Rauchhaus
May 10, 2001·Journal of the American College of Cardiology·T MiyamotoS Sasayama
Jul 2, 2003·Brain, Behavior, and Immunity·Andreas JeronFrank Muders
Sep 9, 2000·Progress in Pediatric Cardiology·M R Anderson
Jun 20, 1998·AACN Clinical Issues·K A Michael, K J Parnell
Aug 25, 2000·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·C B CairnsA Banerjee
May 10, 2002·Circulation Journal : Official Journal of the Japanese Circulation Society·UNKNOWN Effects of Pimobendan on Chronic Heart Failure Study (EPOCH Study)
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·I Bourdel-Marchasson, J P Emeriau
Mar 8, 2000·Cytokine·A MatsumoriS Sasayama
Dec 16, 2006·Basic & Clinical Pharmacology & Toxicology·Pitchai Balakumar, Manjeet Singh
Aug 30, 2012·Journal of Veterinary Emergency and Critical Care·Kimberly L Boyle, Elizabeth Leech
May 6, 2020·International Journal of Molecular Sciences·Luigi Di LuigiCristina Antinozzi
Apr 8, 1998·The American Journal of Physiology·D R Meldrum
Dec 9, 2008·Journal of Combinatorial Chemistry·Sergey A YermolayevSergey M Desenko
Sep 1, 1996·Journal of Cardiac Failure·S Sasayama, A Matsumori

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.